Search research articles

Search research articles

Related Experiment Videos

Escitalopram: a second-generation SSRI.

Michael J Owens¹, Jerrold F Rosenbaum

¹Department of Psychiatry and Behavioral Science, Emory University School of Medicine, Atlanta, Georgia, USA.

|May 8, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Coding Inequities in Psychiatric Care: A Call to Align <i>DSM</i>/<i>ICD</i> With Chronic Disease Management.

The American journal of psychiatry·2025

Same author

Primum Non Nocere: The Onus to Characterize the Potential Harms of Psychedelic Treatment.

The American journal of psychiatry·2025

Same author

Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine.

The Journal of clinical psychiatry·2024

Same author

Anxiety Treatment With Benzodiazepines.

Focus (American Psychiatric Publishing)·2021

Same author

Locus Coeruleus Noradrenergic Modulation of Diurnal Corticosterone, Stress Reactivity, and Cardiovascular Homeostasis in Male Rats.

Neuroendocrinology·2021

Same author

Erratum to "Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor" [Bioorg. Med. Chem. 23 (2015) 4286-4302].

Bioorganic & medicinal chemistry·2020

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Escitalopram, the S-enantiomer of citalopram, is a highly selective serotonin reuptake inhibitor (SSRI) demonstrating superior efficacy and safety for depression treatment compared to its racemate.

Area of Science:

Neuroscience
Pharmacology
Psychiatry

Background:

Serotonin (5-hydroxytryptamine, 5-HT) is implicated in depression.
Selective serotonin transporter (SERT) inhibitors are effective antidepressants.
Citalopram is a selective SSRI with an excellent safety record.

Purpose of the Study:

To evaluate escitalopram, the S-enantiomer of citalopram, as a selective serotonin reuptake inhibitor (SSRI).
To assess the efficacy and safety of escitalopram in treating depression.

Main Methods:

Preclinical animal models of depression.
Pivotal clinical trials comparing escitalopram to citalopram.
Assessment of receptor binding properties and SERT inhibition.

Related Experiment Videos

Main Results:

Escitalopram is the most selective SSRI developed.
Preclinical data predicted escitalopram's effectiveness and double potency versus citalopram.
Clinical trials support escitalopram's efficacy and safety advantages over citalopram.

Conclusions:

Escitalopram demonstrates superior efficacy and safety compared to citalopram.
Escitalopram is a promising first-line antidepressant treatment.
The S-enantiomer, escitalopram, holds significant therapeutic potential for depression.